Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine

Neuron

Volumn 19, Issue 6, 1997, Pages 1285-1296

  Wang, Yan Min ^c   Gainetdinov, Raul R ^a,c   Fumagalli, Fabio ^b,c   Xu, Fei ^c   Jones, Sara R ^c   Bock, Cheryl B ^c   Miller, Gary W ^c   Wightman, R Mark ^c   Caron, Marc G ^c  

^a INSTITUTE OF PHARMACOLOGY   (Russian Federation)

^b UNIVERSITY OF MILAN   (Italy)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; ALCOHOL; AMPHETAMINE; APOMORPHINE; BRAIN MONOAMINE; CARRIER PROTEIN; COCAINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HOMOVANILLIC ACID; LEVODOPA; NORADRENALIN; POTASSIUM; PSYCHOSTIMULANT AGENT; SEROTONIN;

ADOLESCENT; AMINE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; GENE DISRUPTION; LOCOMOTION; MOUSE; NEWBORN; NEWBORN DEATH; NONHUMAN; PRIORITY JOURNAL; SUPERSENSITIVITY; SYNAPSE VESICLE;

EID: 0031458923     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(00)80419-5     Document Type: Article

References (66)

1. Amara, S. (1995). Monoamine transporters: basic biology and clinical implications. Neuroscience 1, 259-268.
2. Banbury Conference on Genetic Background in Mice (1997). Mutant mice and neuroscience: recommendations concerning genetic background. Neuron 19, 755-759.
3. Boakes, R.J., Bradley, P.B., and Candy, J.M. (1971). Supersensitivity of central noradrenaline receptors after reserpine. Br. J. Pharmacol. 43, 443P-444P.
4. Brodie, B.B., Pletscher, A., and Shore, P.A. (1955). Evidence that serotonin has a role in brain function. Science 122, 968-972.
5. Callaway, C.W., Kuczenski, R., and Segal, D.S. (1989). Reserpine enhances amphetamine stereotypes without increasing amphetamine-induced changes in striatal dialysate dopamine. Brain Res. 505, 83-90.
6. Carlsson, A. (1987). Monoamines of the central nervous system: a historical perspective. In Psychopharmacology: the Third Generation of Progress, H.Y. Meltzer, ed. (New York: Raven Press), pp. 39-48.
7. Carlsson, A., Davis, J.N., Kehr, W., Lindqvist, M., and Atack, C.V. (1972). Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase. Naunyn Schmeidebergs Arch. Pharmacol. 275, 153-168.
8. Cooper, J.R., Bloom, F.E., and Roth, R.H., eds. (1996). The Biochemical Basis of Neuropharmacology. (New York: Oxford University Press), pp. 226-409 and 480-510.
9. Daugherty, D.F., Lucey, M.R., and Yamada, T. (1991). Gastric secretion. In Textbook of Gastroenterology. T. Yamada, ed. (Philadelphia: J. B. Lippincott Company), pp. 233-264.
10. Dimaline, R., and Struthers, J. (1996). Expression and regulation of a vesicular monoamine transporter in rat stomach: a putative histamine transporter. J. Physiol. 490, 249-256.
11. Erickson, J.D., and Eiden, L.E. (1993). Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J. Neurochem. 61, 2314-2317.
12. Erickson, J.D., Eiden, L.E., and Hoffman, B.J. (1992). Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci. 89, 10993-10997.
13. Erickson, J.D., Schäfer, M.K.-H., Bonner, T.I., Eiden, L.E., and Weihe, E. (1996). Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc. Natl. Acad. Sci. 93, 5166-5171.
14. Franklin, K.B.J., and Paxinos, G. (1997). The Mouse Brain in Stereotaxic Coordinates (San Diego: Academic Press).
15. Geoge, F.R., and Ritz, M.C. (1991). Common mechanisms of reinforcement from alcohol and other drugs. Alcohol Alcohol Suppl. 1, 427-431.
16. German, D.C., McMillen, B.A., Sanhera, M.K., Saffer, S.I., and Shore, P.A. (1981). Effects of severe depletion on dopamine neuronal impulse flow and on tyrosine hydroxylase regulation. Brain Res. Bull. 6, 131-134.
17. Gonzalez, A.M., Walther, D., Pazos, A., and Uhl, J. (1994). Synaptic vesicular monoamine transporter expression: distribution and pharmacological profile. Mol. Brain Res. 22, 219-226.
18. Hiroi, N., Brown, J.R., Haile, C.N., Ye, H., Greenberg, M.E., and Nestler, E.J. (1997). Fos B mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc. Natl. Acad. Sci. USA 94, 10397-10402.
19. Howell, M., Shirvan, A., Stern-Bach, Y., Steiner-Merdoch, S., Strasser, J.E., Dean, G.E., and Schuldiner, S. (1994). Cloning and functional expression of a tetrabenazine sensitive vesicular monoamine transporter from bovine chromaffin granules. FEBS Lett. 338, 16-22.
20. Johnson, R.G., Jr. (1988). Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol. Rev. 68, 232-307.
21. Kawagoe, K.T., Zimmerman, J.B., and Wightman, R.M. (1993). Principles of voltammetry and microelectrode surface states. J. Neurosci. Methods 48, 225-240.
22. Krejci, E., Gasnier, B., Botton, D., Isambert, M-F., Sagné, C., Gagnon, J., Massoulie, J., and Henry, J.-P. (1993). Expression and regulation of the bovine vesicular monoamine transporter gene. FEBS Lett. 335, 27-32.
23. LaHoste, G.J., and Marshall, J.F. (1992). Dopamine sensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. Synapse 12, 14-26.
24. LaHoste, G.J., and Marshall, J.F. (1994). Rapid development of D1 and D2 dopamine receptor supersensitivity as indicated by striatal and pallidal Fos expression. Neurosci. Lett. 179, 153-156.
25. Lin, P.Y.T., Bulawa, M.C., Wong, P., Lin, L., Scott, J., and Blank, C.L. (1984). The determination of catecholamines, indolamines, metabolites, and related enzymatic activities using three micron liquid chromatography columns. J. Liq. Chromatogr. 7, 509.
26. Liu, Y., and Edwards, R.H. (1997). The role of vesicular transporter proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20, 125-156.
27. + toxicity encodes a vesicular amine transporter. Cell 70, 539-551.
28. + toxicity. Mol. Brain Res. 25, 90-96.
29. Lohof, A.M., Delhaye-Bouchaud, N., and Mariani, J. (1996). Synapse elimination in the central nervous system: functional significance and cellular mechanisms. Rev. Neurosci. 7, 85-101.
30. Long, T.D., and Kathol, R.G. (1993). Critical review of data supporting affective disorder caused by nonpsychotropic medication. Ann. Clin. Psychiatry 5, 259-270.
31. Macon, J.B., Sokoloff, L., and Glowinski, J. (1971). Feed back control of rat brain 5-hydroxytryptamine synthesis. J. Neurochem. 18, 323-331.
32. Maes, M., and Meltzer, H.Y. (1994). The serotonin hypothesis of major depression. In Psychopharmacology: The Fourth Generation of Progress. F.E. Bloom and D.J. Kupfer, eds. (New York: Raven Press), pp. 813-822.
33. Mahata, S.K., Mahata, M., Fisher-Colbrie, R., and Winkler, H. (1993). Vesicle monoamine transporters 1 and 2: differential distribution and regulation of their mRNAs in chromaffin and ganglionic cells of rat adrenal medulla. Neurosci. Lett. 156, 70-72.
34. McNeill, J.H., and Schulze, S. (1972). Reserpine-induced supersensitivity to histamine activated cardiac phosphorylase and cardiac contractility. Res. Commun. Chem. Pathol. Pharmacol. 3, 339-347.
35. Meltzer, H.Y. (1987). Biological studies in schizophrenia. Schizophrenia Bulletin 13, 77-111.
36. Merickel, A., and Edwards, R.H. (1995). Transport of histamine by vesicular monoamine transporter 2. Neuropharmacology 34, 1543-1547.
37. 3H-dihydrotetrabenazine binding in bovine striatal subsynaptic fractions: enrichment of higher affinity binding in a synaptic vesicle fraction. J. Neurochem. 50, 824-830.
38. Müller, E.E. (1995). Role of neurotransmitters and neuromodulators in the control of anterior pituitary hormone secretion. In Endocrinology. L.J. DeGroot, ed. (Philadelphia: W. B. Saunders Company), pp. 178-192.
39. 3H-dihydrotetrabenazine binding to bovine striatal synaptic vesicles. Mol. Pharmacol. 30, 252-257.
40. Nestler, E.J., and Aghajanian, G.K. (1997). Molecular and cellular basis of addiction. Science 278, 58-63.
41. Nirenberg, M.J., Chan, J., Liu, Y., Edwards, R.H., and Pickel, V.M. (1997). Vesicular monoamine transporter 2: immunogold localization in striatal axons and terminals. Synapse 26, 194-198.
42. Peter, D., Finn, J., Klisak, I., Liu, Y., Kojis, T., Heizmann, C., Roghani, A., Sparkes, R., and Edwards, R. (1993). Chromosomal localization of the human vesicular amine transporter genes. Genomics 18, 720-723.
43. Peter, D., Liu, Y., Sternini, C., de Giorgio, R., Brecha, N., and Edwards, R.H. (1995). Differential expression of two vesicular monoamine transporters. J. Neurosci. 15, 6179-6188.
44. Renyi, L. (1986). Long lasting supersensitivity to 5-HT mediated behavior following monoamine depletion in the rat brain. Acta Pharmacol. Toxicol. 59, 298-302.
45. Roberts, M.I., Stadel, J.M., Torphy, T.J., Fleming, W.W., and Taylor, D.A. (1997). Mechanisms of adaptive supersensitivity: Correlation of guinea pig atrial supersensitivity with modifications in adenylyl cyclase activity. Biochem. Pharmacol. 53, 347-356.
46. Robinson, T.E., and Berridge, K.C. (1993). The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18, 247-291.
47. Samson, H.H., and Harris, R.A. (1992). Neurobiology of alcohol abuse. Trends Pharmacol. Sci. 13, 206-211.
48. Scherman, D. (1986). Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J. Neurochem. 47, 331-339.
49. Schildkraut, J.J. (1965). The catecholamine hypothesis of affective disorder: a review of supporting evidence. Am. J. Psychiatry. 122, 509-522.
50. Schuldiner, S., Shirvan, A., and Linial, M. (1995). Vesicular neurotransmitter transporters: from bacteria to humans. Physiol. Rev. 75, 369-392.
51. Seeman, P. (1988). Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J. Clin. Psychopharmacol. 8 (suppl.), 3S-9S.
52. Self, D.W., and Nestler, E.J. (1995). Molecular mechanisms of drug reinforcement and addiction. Annu. Rev. Neurosci. 18, 463-495.
53. Simpson, E.M., Linder, C.C., Sargent, E.E., Davisson, M.T., Mobraaten, L.E., and Sharp, J.J. (1997). Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nature Genet. 16, 19-27.
54. Singer, H.S. (1994). Neurobiological issues in Tourette syndrome. Brain Dev. 16, 353-364.
55. Singer, H.S., Chiu, A.Y., Meiri, K.F., Morell, P., Nelson, P.G., and Tennekoon, G. (1994). Advances in understanding the development of nervous system. Curr. Opin. Neurol. 7, 153-159.
56. Smith, A.D., Olson, R.J., and Justice, J.B., Jr. (1992). Quantitative microdialysis of dopamine in the striatum: effect of circadian variation. J. Neurosci. Methods 44, 33-41.
57. Spector, S., Gordon, R., Sjoerdsma, A., and Udenfriend, S. (1967). End-product inhibition of tyrosine hydroxylase as a possible mechanism for regulation of norepinephrine synthesis. Mol. Pharmacol. 3, 549-555.
58. Surratt, C., Persico, A., Yang, X., Edgar, S., Bird, G., Hawkins, A., Griffin, C.X., Jabs, E., and Uhl, G. (1993). A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies Taql RFLPs. FEBS Lett. 318, 325-330.
59. Thomas, S.A., Matsumoto, A.M., and Palmiter, R.D. (1995). Noradrenaline is essential for mouse fetal development. Nature 374, 643-646.
60. Tybulewicz, V.L.J., Crawford, C.E., Jackson, P.K., Bronson, R.T., and Mulligan, R.C. (1991). Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65, 1153-1163.
61. Weihe, E., Schäfer, M.K.-H., Erickson, J.D., and Eiden, L.E. (1995). Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J. Mol. Neurosci. 94, 149-164.
62. Wilcox, R.E., Smith, R.V., Anderson, J.A., and Riffee, W.H. (1980). Apomorphine-induced stereotypic cage climbing in mice as a model for studying changes in dopamine receptor sensitivity. Pharmacol. Biochem. Behav. 12, 29-33.
63. Wolf, M.E., and Roth, R.H. (1990). Autoreceptor regulation of dopamine synthesis. In Presynaptic Receptors and the Question of Autoregulation of Neurotransmitter Release, S. Kalsner and T.C. Westfall, eds. (New York: N.Y. Academy of Sciences), pp. 323-343.
64. Woolverton, W.L., and Johnson, K.M. (1992). Neurobiology of cocaine abuse. Trends Pharmacol. Sci. 13, 193-200.
65. Zhou, Q.-Y., and Palmiter, R.D. (1995). Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83, 1197-1209.
66. Zhou, Q.-Y., Quaife, C.J., and Palmiter, R.D. (1995). Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 374, 640-643.